Physiology Core

生理学核心（C。罗森，核心总监） Physiology Core的长期目标是提供高质量的体内和体外代谢表型分析 为COBRE项目、其他MaineHealth研究人员和外部研究人员提供服务。一期 取得的成就包括通过收购8 G2扩大和升级我们的代谢表型 HR E-Mitter遥测系统、Seahorse XF 96分析仪、Cytation I细胞成像仪、Faxitron UltraFocus DXA X光机和Sable Systems呼吸测量跑步机，根据我们用户的需求。我们成功 支持我们的COBRE研究人员和非COBRE机构的教师，研究人员和学员，从而 达到我们支持资助赠款申请和出版物的目标指标。在过去的五年里， 最初的四个项目负责人都获得了独立的R 01基金，并且是生理学的经常用户 核心，用于实验服务或咨询罗森博士。他们的研究包括分析细胞 生物能量学、身体组成、代谢和行为研究。此外，我们还成功地 通过与新英格兰大学Solarea Bio的合作项目，提高了外部利用率 （剑桥，MA），Mt.西奈医学院，塔夫茨大学和康奈尔大学。这导致了稳定的 年度服务费收入的增加是可持续发展不可或缺的。使用生理学核心是 在资助一个多PI U19从NIA到Zaidi博士（山。Sinai）和罗森（生理学核心 主任）。发表在PNAS，J Biol Chem，J Clinical Investigation和JCI Insight，eLife，Cancer Research， 《细胞代谢》、《自然通讯》和《细胞报告》是该核心实验的直接结果。 重要的是，生理学核心支持年轻的研究人员接受培训，包括成功的 一架F31和一架F32大多数试点项目获奖者使用了该核心的一个功能， 为本科生提供了与核心设备新技术相关的教育课程 以及研究生和博士后研究员。第二阶段为生理学提供了新的机会 核心是新技术、扩大现有设备的使用和增加培训机会。在 此外，我们最近获得了COBRE设备补充，以扩大新陈代谢的数量， 笼，并在系统内集成温控培养箱。因此，在第二阶段，我们扩大了 我们的设备和能力，以满足高需求的代谢和行为表型，也将 为在热中性和低温下的体内研究提供新的服务。我们将保持我们 高度利用先进的细胞和线粒体生物能量分析服务，除了提供 在研究设计和实施以及数据分析方面提供专家协助。成功的领导， 该核心的管理和操作原则将继续存在，并为项目提供科学支持 领导Lynes、Li和Agarwal博士以及其他MaineHealth和外部研究人员。

Physiology Core (C. Rosen, Core Director) The long-term goal of the Physiology Core is to provide high quality in vivo and in vitro metabolic phenotyping services for COBRE projects, other MaineHealth researchers, and outside investigators. Phase I accomplishments include expanding and upgrading our metabolic phenotyping through the acquisition of 8 G2 HR E-Mitter telemetry systems, a Seahorse XF96 analyzer, a Cytation I cell imager, a Faxitron UltraFocus DXA X-ray machine and a Sable Systems respirometry treadmill, based on our users’ needs. We successfully supported our COBRE investigators and non-COBRE institutional faculty, research staff, and trainees, thereby meeting our targeted metrics for support of funded grant applications and publications. Over the last five years, all four original project leads received independent R01 funding, and were frequent users of the Physiology Core, for experimental services or consultation with Dr. Rosen. Their studies included analysis of cellular bioenergetics, body composition, and metabolic and behavioral studies. Moreover, we have successfully increased outside utilization through collaborative projects with the University of New England, Solarea Bio (Cambridge, MA), Mt. Sinai School of Medicine, Tufts and Cornell Universities. These resulted in steady increases in annual service fee revenue that is integral for sustainability. Use of the Physiology Core was instrumental in the funding of a multi-PI U19 from NIA to Drs. Zaidi (Mt. Sinai) and Rosen (Physiology Core Director). Publications in PNAS, J Biol Chem, J Clinical Investigation and JCI Insight, eLife, Cancer Research, Cell Metabolism, Nature Communications, and Cell Reports were direct results of experiments from this Core. Importantly, the Physiology Core was supportive of young investigators in training, including the successful funding of an F31 and an F32. Most of the pilot project awardees used one of the features of this Core, and educational programs related to new technical aspects for Core equipment were provided to undergraduate and graduate students as well as postdoctoral fellows. Phase II offers new opportunities for the Physiology Core in respect to novel technologies, expanded use of current equipment and greater training opportunities. In addition, we were recently awarded a COBRE equipment supplement to expand the number of metabolic cages and integrate a temperature-controlled incubator within the system. Thus in Phase II, we have expanded our equipment and capacity to meet the high demand for metabolic and behavioral phenotyping, and will also provide new services for in vivo studies at thermoneutrality and at cold temperatures. We will maintain our highly utilized services for advanced cellular and mitochondrial bioenergetic analysis, in addition to providing expert assistance in research study design and implementation and data analysis. The successful leadership, management, and operational principles of this Core will remain in place, and scientifically support the project leads Drs. Lynes, Li, and Agarwal, and other MaineHealth and external investigators.